U.S. Markets open in 7 hrs, 41 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,632.38 | 29.88 | 0.26% |
| NASDAQ | 2,325.88 | 21.92 | 0.95% |
| S&P 500 | 1,282.19 | 5.19 | 0.41% |
| Day Low 10:14 AM EDT | 70.00 | |
|---|---|---|
| Day High 11:19 AM EDT | 72.34 |
|
| Range | 2.34 | |
| Volume | 5.53 M | |
| 30-Day Avg. Vol. | 3.74 M |
|
| Difference | 47.77% | |
| Market Cap. | 20.72 B | |
| Change | 29.02 M | |
| Shares Out. | 293.02 M | |
| Percent Traded | 1.91% | |
| Revenue | 3.17 B | |
| Earnings | 638.2 M | |
| EPS (TTM) | 2.31 |
| 52-Wk Low 12/13/07 | 53.65 | |
|---|---|---|
| 52-Wk High 10/15/07 | 84.75 |
|
| Range | 31.10 | |
| Prev. Close 7/22/08 | 71.28 | |
| Today's Open | 71.41 | |
| Change | 0.18% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.7303 | |
| P/E Ratio (TTM) | 29.13 | |
| P/E Ratio (Fwd.) | 20.00 |
When it comes to developing new and better biotech drugs, Biogen Idec believes two heads are better than one. The biotech giant, formed from the merger of IDEC Pharmaceuticals and Biogen, is focused on ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | 0.793 3/31/08 | 0.83 3/31/08 |
0.037
Beat
|
| Last Quarter | 0.848 6/30/08 | 0.91 6/30/08 |
0.062
Beat
|
| Quarterly - 06/30/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 993.44 M | 3.17 B |
| Gross Profit | 828.17 M | 2.58 B |
| Operating Income | 263.37 M | 865.40 M |
| Net Income | 206.63 M | 638.20 M |
Real-Time Quote
